Contrast Enhanced MRI of the Prostate
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 6/27/2018 |
| Start Date: | November 2014 |
| End Date: | May 2019 |
| Contact: | Xin Li, Ph. D. |
| Email: | lxin@ohsu.edu |
| Phone: | 503-418-1533 |
Prostate cancer detection and disease progression monitoring relies on systematic multi-core
biopsies. Minimal invasive imaging capacities for lesion targeting and monitoring are badly
needed. The purpose of this study is to determine if a new MRI technique can identify and
monitor prostate disease progression. If so biopsy core number can be reduced to as small as
one, and frequency for biopsy repeat can be reduced. The new technique is about a new way of
analyzing the pictures taken as part of prostate MRI exam. This part is called dynamic
contrast-enhanced MRI. It involves an injection of contrast reagent (or dye) through the arm
vein during a time period when prostate MRI pictures are continuously taken.
biopsies. Minimal invasive imaging capacities for lesion targeting and monitoring are badly
needed. The purpose of this study is to determine if a new MRI technique can identify and
monitor prostate disease progression. If so biopsy core number can be reduced to as small as
one, and frequency for biopsy repeat can be reduced. The new technique is about a new way of
analyzing the pictures taken as part of prostate MRI exam. This part is called dynamic
contrast-enhanced MRI. It involves an injection of contrast reagent (or dye) through the arm
vein during a time period when prostate MRI pictures are continuously taken.
The aim of the study is to perform contrast-enhanced (CE) magnetic resonance imaging (MRI) at
OHSU on subjects with diagnosed prostate cancer. This pilot project will study 20 subjects
prior to their next scheduled clinical procedures (biopsy or radical prostatectomy). Data
from this project will be used to explore new capabilities of the software platform developed
under current SBIR funding. CE-MRI will involve the use of an extracellular (Gadolinium
based, Gd) contrast agent. When Gd is used, (dynamic-contrast-enhanced) DCE-MRI signal
intensity time-course data will be analyzed analytically using the so called "shutter-speed"
paradigm which takes into account of the effects of finite water exchange kinetics. Region of
interest (ROI) and high resolution (~millimeter) parametric maps of pathophysiologic
quantities, such as tumor vessel permeability, tumor perfusion, extracellular extravascular
volume fraction, will be generated from the DCE-MRI data. All parameters will be compared to
literature results for software validation and correlated with pathology for clinical
potential.
OHSU on subjects with diagnosed prostate cancer. This pilot project will study 20 subjects
prior to their next scheduled clinical procedures (biopsy or radical prostatectomy). Data
from this project will be used to explore new capabilities of the software platform developed
under current SBIR funding. CE-MRI will involve the use of an extracellular (Gadolinium
based, Gd) contrast agent. When Gd is used, (dynamic-contrast-enhanced) DCE-MRI signal
intensity time-course data will be analyzed analytically using the so called "shutter-speed"
paradigm which takes into account of the effects of finite water exchange kinetics. Region of
interest (ROI) and high resolution (~millimeter) parametric maps of pathophysiologic
quantities, such as tumor vessel permeability, tumor perfusion, extracellular extravascular
volume fraction, will be generated from the DCE-MRI data. All parameters will be compared to
literature results for software validation and correlated with pathology for clinical
potential.
Inclusion Criteria:
- Men, age >18 years.
- Any patient scheduled for prostate biopsy repeat or radical prostatectomy.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Patients who would be normally excluded from undergoing an MRI examination - patients
with a pacemaker, aneurysm clip or any other condition that would warrant avoidance of
a strong magnetic field.
- Patients who are unable to cooperate for an MRI exam.
- Major surgery within a month of enrollment.
- Prostate biopsy six weeks prior to enrollment.
- Subject-reported reaction to gadolinium contrast reagent.
We found this trial at
1
site
Click here to add this to my saved trials
